Table 2.
Switching patterns among new users of antidiabetic drugs initiated on either metformin or a sulphonylurea.
| Therapy at the index date | Total switchers | Treatment switching | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Metformin | Sulfonylureas | Alpha glucosidase inhibitors | £DPP-4 inhibitor | Repaglinide | Thiazolidinediones | GLP-1 | 1SGLT2 | Insulin | P-value | ||
| Total N = 11,228 | 1,414 (12.6%) | 253 (17.9%) | 340 (24.1%) | 109 (7.7%) | 158 (11.2%) | 197 (13.9%) | 33 (2.3%) | 108 (7.6%) | 133 (9.4%) | 147 (10.4%) | |
| Metformin: ( N = 10,246) | 1,068 (10.4%) | – | 332 (31.1%) | 98 (9.2%) | 105 (9.8%) | 176 (16.5%) | 22 (2.1%) | 102 (9.6%) | 123 (11.5%) | 122 (11.4%) | <0.001* |
| Comorbidity score (Mean ± SD) | 3.5 ± 2.8 | 3.4 ± 2.9 | 4.3 ± 2.8 | 3.2 ± 2.6 | 4.1 ± 3.2 | 3.5 ± 3.0 | 2.5 ± 2.1 | 2.6 ± 2.1 | 3.9 ± 3.0 | <0.001* | |
| Sulfonylurea: ( N = 982) | 346 (35.2%) | 253 (73.1%) | 8 (2.3%) | 11 (3.2%) | 53 (15.3%) | 21 (6.1%) | 11 (2.9%) | 6 (1.7%) | 10 (2.9%) | 25 (7.2%) | 0.610 |
| Comorbidity score (Mean ± SD) | 3.2 ± 3.0 | 3.1 ± 2.7 | 5.8 ± 7.2 | 3.2 ± 2.6 | 2.6 ± 3.0 | 4.8 ± 3.0 | 3.7 ± 2.8 | 2.8 ± 3.0 | 2.6 ± 2.2 | 2.6 ± 2.8 | 0.125 |
*P-value less of 0.05 was considered to be statistically significant. £ DPP-4, dipeptidyl peptidase-4 inhibitors; ºGLP-1, glucagon-like peptide-1 receptor agonists; 1 SGLT-2, sodium-glucose co-transporter-2 inhibitors.